Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropathic Pain and Neurodegenerative Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for BEGAIN drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | BEGAIN Recombinant Protein (Functional Domains) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for PPI assays. |
View BEGAIN Products |
| Gene Delivery | BEGAIN Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and synaptic localization studies. |
View BEGAIN Products |
| Benchmark Ab | Anti-BEGAIN Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View BEGAIN Products |
| Validator | BEGAIN siRNA Set For knockdown verification in neuronal cell models. |
View BEGAIN Products |
| Related Target A | DLG4 (PSD-95) Scaffolding protein that directly interacts with BEGAIN; critical for synaptic PPI targeting. |
View DLG4 Products |
| Related Target B | DLGAP1 (SAPAP1) Interacting partner in the postsynaptic density complex involved in neuropsychiatric pathways. |
View DLGAP1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Protein-Protein Interaction (PPI) Screening | Specifically truncated BEGAIN domains (e.g., GK-binding region) expressed with high purity (>95%) for SPR/BLI assays. |
| Synaptic Targeting Verification | Sequence-verified Lentivirus for stable expression of tagged BEGAIN to track localization. |
| Lack of Controls | Sequence-defined Recombinant Antibodies included for assay benchmarking. |
| False Positives | Validated siRNA sets included for target-specific knockdown verification. |
Live BEGAIN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of BEGAIN (Brain-enriched guanylate kinase-associated protein) is an emerging frontier in neuropharmacology. As a key adapter protein within the postsynaptic density (PSD) of glutamatergic synapses, BEGAIN is increasingly recognized as a critical node in chronic pain transmission and neurodegenerative pathology. The race for BEGAIN therapeutics is intensifying, with major players shifting focus from traditional systemic neuromodulators to localized protein-protein interaction (PPI) disruptors. As first-generation synaptic scaffold modulators reach the clinic, the next wave of R&D is targeting the specific disruption of the BEGAIN-PSD-95 complex to alleviate neuropathic pain without the cognitive side effects associated with direct NMDA receptor antagonism.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Medical Centers, Emerging Biotechs | Neuropathic Pain, Chronic Inflammatory Pain | In vitro binding assays (Need high-purity recombinant BEGAIN domains) |
| Gene Therapy (RNAi/AAV) | Neuroscience-focused Gene Therapy Firms | Synaptic Dysfunction, Neurodegenerative Diseases | Transfection and knockdown validation (Need sequence-verified siRNA and Lentivirus) |
| Antibody/Peptide Conjugates | Specialty CNS Therapeutics Companies | Refractory Pain Pathways | Epitope mapping and delivery validation (Need recombinant positive controls) |